-
News
IRON RIVER – Aspirus Iron River Hospital & Clinics recently performed the first esophageal impedance testing case in Michigan. This milestone marks a significant advancement in diagnostic capabilities for Gastroesophageal Reflux Disease (GERD)
MiVu is a new approach to assessing Esophageal Mucosal Integrity, offering instantaneous detection of conditions such as Gastroesophageal Reflux Disease (GERD), Eosinophilic Esophagitis (EoE) and Non-GERD-related esophageal disorders, all of which can cause significant discomfort and affect daily life. MiVu also provides the ability to monitor treatment responses with unprecedented accuracy and efficiency.
GERD often leads to heartburn, regurgitation and chest pain, while EoE manifests with difficulty swallowing, food impaction and persistent heartburn. Non-GERD-related esophageal disorders may present with symptoms such as difficulty swallowing, painful swallowing or chronic cough.
Undergoing endoscopic procedures like MiVu esophageal impedance testing allows individuals with these conditions to find relief by identifying and addressing the root cause of their symptoms. Monitoring these conditions is crucial to ensure proper treatment and to prevent complications like esophageal strictures or Barrett’s esophagus.
“We are thrilled to lead the way in Michigan by introducing MiVu esophageal impedance testing,” said Dr. Medhat Fanous, MD, Director of the anti-reflux program at Aspirus Iron River Hospital & Clinics. “This innovative technology revolutionizes our diagnostic capabilities, providing clinicians with real-time insights into esophageal health and enabling more personalized and effective patient care. We are proud to comprehensively diagnose and treat reflux using cutting-edge technology in a rural hospital in the Upper Peninsula of Michigan.”
Esophageal impedance testing with MiVu offers several key advantages over traditional diagnostic methods. By leveraging advanced technology, clinicians can swiftly identify underlying conditions and tailor treatment plans accordingly, enhancing patient outcomes and quality of life.
“Aspirus Health remains committed to advancing healthcare excellence in our community and beyond,” said Rae Kaare, Chief Administrative Officer at Aspirus Iron River. “The introduction of MiVu reinforces our mission to heal people, promote health and strengthen communities.”
With this milestone achievement, Aspirus Health is dedicated to delivering revolutionary solutions and comprehensive services to improve the health and well-being of individuals across Michigan, Wisconsin and Minnesota.
“This is truly a history-making moment,” said Dave Lorenson, Manager – Surgical Services. “Our patients have access to high quality care close to home.”
For more information on anti-reflux, MiVu esophageal impedance testing or other innovative healthcare services offered by Aspirus Iron River Hospital & Clinics, call 906-265-6121 or visit aspirus.org.